Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)
Status:
Completed
Trial end date:
2020-09-09
Target enrollment:
Participant gender:
Summary
To evaluate the long-term impact of treatment with sertraline on aspects of cognitive,
emotional and physical development and pubertal maturation in pediatric subjects ages 6 to 16
years (inclusive) with a diagnosis of anxiety disorder, depressive disorder or obsessive
compulsive disorder.
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.